The mission of the Mass Spectrometry Shared Resource (MSSR) is to provide Cancer Therapy &Research Center (CTRC) members and University of Texas Health Science Center (UTHSCSA) investigators with comprehensive, state-of-the-art support for characterization and quantification of proteins, metabolites and other biomedically important molecules using mass spectrometry. The MSSR has been in operation since 1979 and became a Cancer Center Shared Resource in 1998. There are two components of the MSSR, proteomics and metabolomics, which operate at two locations, a 713 sq. ft. space (Proteomics) on the Long (main) campus of the UTHSCSA and a 782 sq. ft. space (Metabolomics) on the Greehey (north) campus of the UTHSCSA in the South Texas Research Facility (STRF). The MSSR is jointly managed by the University and the CTRC. The MSSR services include molecular mass determination, protein identification, protein quantification, sequence characterization of peptides, localization covalent modification, and metabolomics (discovery experiments, targeted quantitative analysis, and small molecule analysis by GC-MS). The shared resource also offers consultations and training to CTRC investigators. The MSSR is directed by Susan Weintraub, Ph.D. The staff of the MSSR includes two-technical Directors, Kevin W. Hakala, M.S, (Proteomics) and Xiaoli Gao, Ph.D., (Metabolomics) with Sam Pardo as the Core Facilities Technologist. The MSSR team has expertise in the use of mass spectrometry to solve important cancer-related questions. During the last award year, the MSSR serviced 14 peer-review funded cancer center members, which comprised 19% of the total core users and contributed to 29 cancer-related peer-reviewed publications during the last funding period. Usage for the first half of 2013 increased two-fold, likely due to the addition of Metabolomics as a service.

Public Health Relevance

The MSSR supports CTRC investigators who are studying many different aspects of cancer related to fundamental processes, cancer metastasis, and cancer treatment. Analyses of proteins, peptides, small molecule metabolites, and candidate therapeutic agents are conducted by expert technical staff. These efforts provide essential information to elucidate mechanisms of cancer development and assess better ways to treat this deadly disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M3))
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Health Science Center
San Antonio
United States
Zip Code
Zanotto-Filho, Alfeu; Dashnamoorthy, Ravi; Loranc, Eva et al. (2016) Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human. PLoS One 11:e0153970
Newcomb, Lisa F; Thompson Jr, Ian M; Boyer, Hilary D et al. (2016) Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol 195:313-20
Ortiz, Carmen; Morales, Luisa; Sastre, Miguel et al. (2016) Cytotoxicity and Genotoxicity Assessment of Sandalwood Essential Oil in Human Breast Cell Lines MCF-7 and MCF-10A. Evid Based Complement Alternat Med 2016:3696232
Price, Douglas K; Chau, Cindy H; Till, Cathee et al. (2016) Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer 122:2332-40
Zanotto-Filho, Alfeu; Masamsetti, V Pragathi; Loranc, Eva et al. (2016) Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. Mol Cancer Ther 15:3000-3014
Sareddy, Gangadhara R; Li, Xiaonan; Liu, Jinyou et al. (2016) Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Sci Rep 6:24185
Sweeney, Shannon R; Kavanaugh, Arthur; Lodi, Alessia et al. (2016) Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. RMD Open 2:e000289
Schenk, Jeannette M; Till, Cathee; Hsing, Ann W et al. (2016) Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control 27:175-82
Toledo, Rodrigo A; Qin, Yuejuan; Cheng, Zi-Ming et al. (2016) Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res 22:2301-10
Wu, Anqi; Dong, Qiaoxiang; Gao, Hui et al. (2016) Characterization of mammary epithelial stem/progenitor cells and their changes with aging in common marmosets. Sci Rep 6:32190

Showing the most recent 10 out of 853 publications